direction that would have been hypothesized before the trial. Thus, although one must be cautious in the interpretation of subgroup analyses, there is a strong probability that the interaction is real. Therefore, my view on the results is that acetazolamide has a beneficial effect of clinically meaningful magnitude on visual field when Grade 3-5 papilledema is present but when papilledema is milder, the IIHTT results do not support prescribing acetazolamide in a typical case if the goal of treatment is to provide a beneficial effect on visual field. However, there might be other reasons to prescribe acetazolamide for IIH with Grade 1-2 papilledema such as to treat headaches or if the papilledema appears to be worsening or is associated with any degree of optic disc pallor. It would be useful to examine the quality of life results stratified by baseline degree of papilledema to see if they are concordant with the stratified visual field results.
In a large randomized trial, we generally learn a great deal more than just information about the effect of treatment. From the ONTT clinical trial and subsequent longitudinal data, more than 30 articles were published in addition to the primary treatment group comparison covering a wide range of topics, including the natural history of vision following optic neuritis (from the control group), the relationship of optic neuritis to multiple sclerosis, systemic side effects of corticosteroids in a systemically healthy cohort of patients, characteristics of optic neuritis visual field defects, and visual function changes in the fellow eye. The IIHTT already has published 8 articles covering a variety of topics, including the quality of life of patients with IIH (5), characteristics of patients with IIH (6), visual field findings with IIH (7), relationship of baseline optical coherence tomography (OCT) to clinical features (8), OCT methodology (9), papilledema outcomes assessed with OCT (10), factors associated with acetazolamide response (11) , and factors associated with a poor visual outcome from IIH (12) .
In this issue of the Journal, the IIHTT adds 2 more articles to the literature, providing further information about visual field testing in IIH and about side effects occurring with acetazolamide. The main objective of the visual field article by Cello et al (13) was to determine how frequently abnormal visual fields in IIH are due to true worsening of disease as opposed to what the authors term a "performance failure." Performance failures were defined as either (1) visual field results met treatment failure criteria on 1 field that were not confirmed on a second field, or (2) deterioration was confirmed on the retest but the adjudication committee concluded that true worsening due to IIH was unlikely. The article by Cello et al presents data showing that only 4% of participants had a treatment failure, whereas 21% had at least 1 abnormal visual field considered to be a performance failure. The point to take away in caring for patients with IIH is that a visual field with a worsened mean deviation is more likely to be related to the patient's performance than to a true worsening of the condition and as such should be repeated before concluding that any worsening is real. Furthermore, the study showed that 87% of the perimetry results classified as a performance failure had "reliability criteria" calculated by the perimeter software within normal limits. Therefore, the perimeter's reliability criteria are not useful for judging whether a visual field change is real and it is only through repeat testing that this determination can be made.
The report by ten Hove et al (14) shows one of the benefits of having a placebo group in a randomized trial. With a placebo group for comparison, an assessment can be made about the side effects occurring with a treatment. Although side effects as expected were greater with acetazolamide than placebo, the proportion of participants reporting side effects with placebo was not trivial. For instance, 22% of the placebo group reported gastrointestinal adverse effects. The acetazolamide results need to be interpreted in the context of the dose used in the trial of up to 4 grams per day of acetazolamide, a dose higher than some prescribe in usual practice. Only 44% of the acetazolamide-treated patients were able to tolerate 4 g per day but most tolerated 1 gram per day for the 6-month period of the trial. Therefore, the clinical points to take home are that although 6 months of acetazolamide produces more side effects than placebo, it is generally safe and as shown in the primary article, side effects did not seem to overly influence the participants' quality of life assessment. It is reasonable to strive to achieve the dose of 4 grams per day prescribed in the IIHTT but a lower dose may be effective; therefore, the maximum tolerated dose should be the goal. It is unknown whether a dose of 4 grams per day is better, if tolerated, than a lower dose, and it is not possible to discern this from the IIHTT data, because an analysis based on the dose used in the trial potentially would be biased because the willingness to tolerate a higher dose might be related to perceived benefit on the part of the participant.
The IIHTT is an important trial for neuroophthalmology. The trial leadership, investigators, coordinators, and the NORDIC organization are to be congratulated for conducting an excellent clinical trial that has furthered knowledge for how to treat patients with IIH and mild visual field loss, and, like other large randomized trials, the IIHTT has contributed to knowledge about IIH in many other important ways.
